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Abstract
Background Variation exists in the resource categories
included in economic evaluations, and National Institute
for Health and Care Excellence (NICE) guidance suggests
the inclusion only of costs related to the index condition or
intervention. However, there is a growing consensus that
all healthcare costs should be included in economic eval-
uations for Health Technology Assessments (HTAs), par-
ticularly those related to extended years of life.
Objective and Methods We aimed to quantify the impact
of a range of cost categories on the adoption decision about
a hypothetical intervention, and uncertainty around that
decision, for stable coronary artery disease (SCAD) based
on a dataset comprising 94,966 patients. Three costing
scenarios were considered: coronary heart disease (CHD)
costs only, cardiovascular disease (CVD) costs and all
costs. The first two illustrate different interpretations of
what might be regarded as related costs.
Results Employing a 20-year time horizon, the highest
mean expected incremental cost was when all costs were
included (£2468) and the lowest when CVD costs only
were included (£2377). The probability of the treatment
being cost effective, estimating health opportunity costs
using a ratio of £30,000 per quality-adjusted life-year
(QALY), was different for each of the CHD (70%) costs,
CVD costs (73%) and all costs (56%) scenarios. The results
concern a hypothetical intervention and are illustrative
only, as such they cannot necessarily be generalised to all
interventions and diseases.
Conclusions Cost categories included in an economic
evaluation of SCAD impact on estimates of both cost
effectiveness and decision uncertainty. With an aging and
co-morbid population, the inclusion of all healthcare costs
may have important ramifications for the selection of
healthcare provision on economic grounds.
Key Points for Decision Makers
Variation exists in the resource categories included
in economic evaluations, and National Institute for
Health and Care Excellence (NICE) guidance
suggests the inclusion only of costs related to the
index condition or intervention.
Cost categories included in an economic evaluation
of stable coronary artery disease significantly impact
on estimates of cost effectiveness and decision
uncertainty.
1 Introduction
Interventions in patients with coronary heart disease (CHD)
or at risk of CHD present significant costs to the UK
National Health Service (NHS), may reduce the risks of
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CHD events such as acute myocardial infarction (MI), may
reduce the risk of other (non-CHD) health events and can
potentially improve survival patients [1, 2]. One example is
the prescription of statins (HMG-CoA reductase inhibitors)
as primary prevention for CHD, which has attracted con-
troversy due to the potential high up-front cost but a
potential overall net saving due to reduced future CHD
costs as well as wider cardiovascular disease (CVD) costs
such as those of strokes avoided [1]. Yet the statins may
also increase life expectancy and costs will be incurred by
the NHS during these extended years of life [3, 4].
In an economic evaluation the incremental costs incur-
red by a new intervention and the health benefit it generates
are compared to the health benefit of activities that could
have been funded with the same resources elsewhere [5].
There is extensive debate, however, around what types of
costs should be included in estimating the incremental
costs of a new intervention [6, 7], and what costs are
included can have material impacts on the expected cost
effectiveness and the associated uncertainty. This can
affect the decisions reached by policy makers, e.g. whether
to approve or reject the new intervention unconditionally,
or whether to recommend an alternative coverage decision
such as coverage with evidence development [8–10]. This
paper considers the importance of the choice of costs to
include using a hypothetical intervention that reduces the
risk of CVD events in patients with stable coronary artery
disease (SCAD).
The debate considers two types of costs: related and
unrelated. Garber and Phelps [11] define unrelated costs as
those that are independent of the intervention under con-
sideration, and in cases where treatments extend life costs
are defined as unrelated if they are independent of treat-
ment but conditional on survival. Conversely, all other
costs that are not independent are defined as related.
National Institute for Health and Care Excellence (NICE)
guidance [12] explicitly makes the recommendation that
‘‘costs that are considered to be unrelated to the condition
or technology of interest should be excluded’’.1 A posited
theoretical justification for this recommendation is that the
aim of economic evaluation is to judge each intervention
on its own ‘merits’ [13]. For example, it is argued that the
inclusion of future unrelated costs can increase the likeli-
hood of a life-extending technology being judged to not be
cost effective even at zero price, which may seem counter-
intuitive [7, 14]. The second US Panel on Cost-effective-
ness in Health and Medicine, however, recommends that
all current and future, related and unrelated healthcare
costs should be included in cost-effectiveness analysis.
This reflects a growing consensus that all healthcare costs
should be included, particularly in extended years of life
[3, 15]. Indeed, the guidelines employed in the Netherlands
and by the LFN (Dental and Pharmaceutical Benefits
Board) in Sweden [16] also recommend the inclusion of
future unrelated costs [17].2
In practice, whether costs are related or unrelated is
based on a judgement of whether they are plausibly related
to either the condition or the intervention being considered.
This is a subjective assessment and is argued to result in
analyses that impose arbitrary restrictions on the costs that
are considered relevant [18]. Further, it is not always clear
which costs are related and which are unrelated to the
condition or intervention. One such example is the case of
acute MI and, in particular, how it affects survivors in
terms of life expectancy and the likelihood of experiencing
health events or diseases in later life (20.72% of patients
with SCAD are MI survivors in the CALIBER [ClinicAl
research using Linked Bespoke studies and Electronic
Records] dataset [19]). MI survivorship is increasing due to
the availability of effective treatments; for example, in
England in 2010, on average, 27.32% of MI cases that were
admitted to hospital died within 30 days, where the cor-
responding 2002 proportion was 37.18% [20].
A review of published economic evaluations of the
treatment of MI finds considerable variation in the types of
costs included, reflecting both the subjectivity in deter-
mining relevance and variation in recommendations among
guidelines. Nineteen economic evaluations published since
2006 are categorised according to the cost categories
included: CHD costs only, CVD costs only or all costs (see
Electronic Supplementary Material Appendix). CHD costs
form the smallest cost category, including costs exclusively
related to CHD, e.g. costs attributable to MI. CVD costs
include not only all costs attributable to CHD but all costs
related to the cardiovascular system more broadly, e.g.
ischaemic and haemorrhagic stroke. The CHD costs cate-
gory is therefore a subset of the CVD costs category. These
categories are both subsets of the all costs category, where
all costs are included regardless of to which health condi-
tions they are attributable, e.g. they therefore include CVD
and non-CVD costs such as those attributable to cancer. Of
the 19 studies, five were found to include CHD costs only,
eight CVD costs only and six evaluations included all
costs. The main difference between studies including CVD
costs rather than CHD costs was that costs from stroke
events were included. Studies considering related costs
only tended to be those that were trial-based analyses,
where only CHD/CVD-related data were recorded, or
1 A fuller discussion of guidelines and recommendations pertaining
to the exclusion of unrelated costs (in particular those in extended
years of life) can be found elsewhere [41].
2 A further debate surrounds the inclusion of non-healthcare costs, as
recommended by the guidelines of the Netherlands and Sweden. This
remains more controversial and is beyond the scope of this paper.
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model-based approaches including only CHD or CVD
events. One observational data study considered only CVD
costs where the analysis was performed on a dataset with
detailed information collected on only a select number of
CVD endpoints [21]. Of those studies that incorporated
non-CVD costs, it is informative to consider the different
approaches taken. One study was based on a trial that had
collected a wide range of types of resource use [22].3
Model-based analyses used a number of different approa-
ches: national averages [23], age-specific costs from risk-
adjustment studies [24, 25], estimates of lifetime costs
obtained from registry data and use of expert opinion [26].
Finally, for one study undertaking an analysis of observa-
tional data, all costs were included in the analysis as the
default, but a sensitivity analysis was undertaken in which
only costs with the ischaemic heart diseases International
Classification of Diseases (ICD) code were included [27].
Given the variation in practice by analysts in conducting
economic evaluations of MI treatment and the difficulty in
distinguishing what costs are related from those that are
not, it is important to consider the implications of which
costs are included in an economic evaluation. In this paper
a recently published ‘real-world’ cost-effectiveness model
is used to consider a hypothetical intervention that reduces
the risk of CVD health events for patients with SCAD to
investigate the impact of including different cost categories
on expected cost effectiveness and decision uncertainty.
This analysis represents the first attempt to consider the
implications of collecting broader cost data not only in
terms of addressing concerns around the expected incre-
mental costs, but also in terms of any impacts upon the
associated decision uncertainty.
2 Methods
In order to illustrate and quantify the importance, in terms
of incremental cost and decision uncertainty, of the ana-
lyst’s decision around which cost categories to include,
three different scenarios are specified using the CALIBER
model [28]. The three scenarios pertain to the range of
costs that are included in each analysis: CHD costs only,
CVD costs or all costs. Full details of the model are pre-
sented elsewhere [28] but, in brief, the CALIBER model
employs a set of risk equations estimating probabilities of
subsequent MI, ischaemic and haemorrhagic stroke and
mortality that are structured as a Markov model to model
disease progression in a secondary prevention of CHD
context [28]. These equations are estimated using data from
four data sources (detailed in Denaxas et al. [29]): the
Clinical Practice Research Database (CPRD), Myocardial
Ischaemia National Audit Project (MINAP) registry,
Hospital Episode Statistics (HES) and Office for National
Statistics (ONS).4 It is assumed that a hypothetical treat-
ment administered to patients in the SCAD health state at a
cost of £250 per year reduces the probability of potentially
fatal cardiovascular health events compared with a stan-
dard care control group, with a relative risk of 0.8. The
patient cohort modelled is assumed to be in the fifth decile
of 5-year risk of a composite CVD first event.
The model is evaluated probabilistically, with 999 itera-
tions run in total. For each iteration of the model eight key
results are recorded: quality-adjusted life-years (QALYs)
associated with the intervention and control groups and costs
associated with the intervention and control groups,
according to three different costing scenarios. Two of the
three scenarios represent plausible approaches to including
only related costs as per the NICE guidance on this issue, one
of which is narrow and the other slightly broader. In the CHD
costs only and CVD costs only scenarios, only healthcare
costs that are identifiable as CHD and CVD through the ICD
10th edition (ICD-10) codes of the recordedHealthResource
Group (HRG) are included.5 The third scenario includes all
healthcare costs and so represents an approach where no
distinction is drawn in terms of related and unrelated costs. In
all scenarios, incremental discounted costs and QALYs are
evaluated at a time horizon of 20 years (equivalent to a
lifetime time horizon given the starting age of the cohort
[mean age at cohort entry was 65 years for males and
73 years for females], where the lifetime time horizon is the
recommended choice for treatments that will impact on
mortality [5]) using an annual discount rate of 3.5% for both
costs and QALYs, and the net health benefit is calculated
using £30,000 per QALY [12]. It is not possible within this
model to separate out the implications of including different
cost categories into effects from unrelated costs in extended
years of life and those in years of life not extended by the
intervention as the treatment has both morbidity and mor-
tality impacts. However, the relative size of the effect of
extended years of life will be smaller with shorter time
horizons and so we present some results to show the effect of
time horizon on cost effectiveness and decision uncertainty.
3 Interestingly, in this study one of the resource use measures that
was particularly high for one patient among those treated was
considered by the authors to only be ‘‘weakly related’’ to the
intervention and so was excluded as part of the sensitivity analysis,
which had quite a large effect on the mean cost difference [22].
4 Further details given in Asaria et al. [28] and Walker et al. [42].
Resource use is taken from administrative data sources, CPRD and
HES, and then costed on the basis of NHS reference costs, Personal
Social Services Research Unit (PSSRU) unit costs and NHS
prescription cost analysis [43–45]. Estimation of cost parameters in
the model is undertaken using the panel data approach outlined in
Walker et al. [42].
5 CHD HRGs were defined as those with ICD-10 codes from I10
through to I52.
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3 Results
Cost results are first considered in isolation. The mean
costs in the treated and control groups are presented along
with summary statistics of the incremental costs, illustrat-
ing the effect of the three different scenarios on the loca-
tion and dispersion of the distribution of estimated
incremental costs, in Table 1.
Mean costs over a 20-year time horizon for both the
treated and control groups increase with the inclusion of
additional cost categories. In terms of incremental costs,
including all costs results in the highest mean incremental
cost. The CVD costs only scenario gives the lowest mean
incremental cost. Variability of incremental costs increases
when more cost categories are included based on the width
of the 95% credibility interval. The distribution of incre-
mental costs is presented in Fig. 1.
Figure 1 shows the distributions of incremental costs
under each scenario. Mean incremental costs were lowest
in the CVD costs only scenario and highest in the all costs
scenario. The distributions of incremental costs under
scenarios with more cost categories included are consid-
erably wider, reflecting greater variability.
To investigate the relative effect of unrelated costs in
extended years of life compared with those in life-years not
extended by the intervention, we investigate the distribu-
tion of incremental costs for different time horizons up to
20 years, with changes over time likely to reflect the
increasing impact of costs in extended years of life. These
results are summarised in Figs. 2 and 3.
Figure 2 shows the credibility interval of the incre-
mental costs for two different cost category scenarios
(CHD and all costs) against the time horizon. It can be seen
that with longer time horizons, such as 20 years, the all
costs scenario produces higher incremental costs on aver-
age. Looking at the shorter time horizons the opposite is
found, with incremental costs on average higher under the
CHD scenario. Variability, seen from the width of the
credibility interval shown in Fig. 3, is higher for the all
costs scenario at all time horizons. For both scenarios,
variability increases with the time horizon.
It is also useful to consider the impact of incremental
costs on cost effectiveness in order to illustrate how these
findings could affect decision-making and decision uncer-
tainty. In all scenarios the mean incremental QALY from
treatment is 0.084. These are the denominators in the
estimates of the incremental cost-effectiveness ratios
(ICERs) provided in Table 2, where the numerators are the
mean incremental costs reported in Table 1.
For illustrative purposes we consider a decision maker
who regards a treatment as cost effective when the ICER is
less than £30,000 per QALY gained [12]. Whilst the
treatment is expected to be cost effective in all scenarios
(all of the ICERs are below £30,000 per QALY), it can be
seen that the choice of cost categories that are included is
likely to influence the degree of decision uncertainty.
Figure 4 shows the distributions of net health benefits for
the treatment. The treatment is cost effective when the net
health benefit is greater than zero.
The proportion of iterations with a positive net health
benefit, i.e. the probability of being cost effective, varies
across the three scenarios: CHD costs (70%), CVD costs
(73%) and all costs (56%). These percentages reflect the
distribution of net health benefit in the different scenarios
where both the location and dispersion of the distributions
is influenced by the choice of cost categories to be
included.
4 Discussion
This paper assesses the cost effectiveness of a hypothetical
intervention using a previously published model based on
‘real-world’ data to demonstrate that the inclusion of
unrelated costs will affect both the mean incremental costs,
ICER and decision uncertainty.
Unambiguously, costs will be greater when more cate-
gories are included (given costs are non-negative). It is
harder to predict how the different cost category scenarios
will affect the estimated incremental costs that are required
for economic evaluation. The treatment under considera-
tion here reduces the risk of cardiovascular events, each
with associated CHD, CVD and non-CVD costs, in normal
Table 1 Summary statistics of costs and incremental costs at a time
horizon of 20 years
Statistics Resource categories included
CHD (£) CVD (£) All (£)
Mean ct 29,117 36,310 50,202
Mean cc 26,721 33,934 47,734
Mean ct- cc 2396 2377 2468
Minimum ct- cc 2287 2232 2273
Maximum ct- cc 2523 2547 2686
Range ct- cc 237 315 414
Standard deviation ct- cc 39 53 69
Median ct- cc 2394 2374 2468
Q0.025 ct- cc 2323 2281 2343
Q0.975 ct- cc 2471 2478 2595
95% credibility interval ct- cc 148 197 252
CHD coronary artery disease, CVD cardiovascular disease, cc cost
when control, ct cost when treated, Q0.025 2.5th percentile, Q0.975
97.5th percentile
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Fig. 1 Frequency plot of incremental costs under three scenarios. CHD coronary heart disease, CVD cardiovascular disease
Fig. 2 95% credibility interval (CI) against time horizon by costing scenario. CHD coronary artery disease, cc cost when control, ct cost when
treated, Q0.025 2.5th percentile, Q0.975 97.5th percentile
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years of life (i.e. not extended years of life). Each of these
events is potentially fatal, and so the treatment extends life.
This distinction is important when thinking about the overall
effect on incremental costs. In normal years of life, including
more cost categories increases the magnitude of the cost
savings that are brought about by the reduced risk of cardio-
vascular events.6 However, including additional cost cate-
gories means greater costs in extended years of life resulting
from the treatment. As such, these two effects offset one
another to some extent.7 Therefore, the overall effect is
ambiguous. Moving from only CHD costs to CVD costs
reduces themean incremental cost, becausemore cost savings
(e.g. from reduced strokes) are captured during normal years
of life than the additional incremental CVD costs captured in
extended years of life resulting from the treatment. However,
moving from either CHD costs only or CVD costs only to
including all costs increases the incremental costs overall
because the extended years of life effect outweighs the effect
of capturing more savings during normal years of life.
Fig. 3 Width of 95% credibility interval against time horizon by costing scenario. CHD coronary heart disease, CI 95% credibility interval
Table 2 Estimated incremental
cost-effectiveness ratios in the
different costing scenarios
Resource categories included
CHD CVD All
ICER £28,626 per QALY £28,395 per QALY £29,485 per QALY
CHD coronary heart disease, CVD cardiovascular disease, ICER incremental cost-effectiveness ratio, QALY
quality-adjusted life-year
6 Note that this holds only if the excluded cost categories are not truly
unrelated. 7 Authors have noted this kind of offset in previous applications [46].
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Unfortunately, given the model used, it is not possible to
separate out these effects and only the joint effect is observ-
able. However, by considering shorter time horizons we can
examine the relative impacts of costs in normal and extended
years of life. With a shorter time horizon the effect of costs in
normal years of life is relatively more influential and so the
direction of effect on the cost effectiveness of the ambiguous
relationship between inclusion of broader cost categoriesmay
vary with the time horizon. Indeed, this is what is seen in our
results. At very short time horizons, the incremental costs are
on average higher when restricted to CHD costs only than
when including all cost categories. The variability of costs is
higher for all costs than it is for CHD costs at all time horizons
analysed. This would translate to greater decision uncertainty
when including all costs, ceteris paribus, even when using
short time horizons.
In addition to the effect on mean incremental costs, this
paper also explores the effect that the different scenarios
have on decision uncertainty. Again, this effect needs to be
thought of as two separate underlying processes. The first
of these is, when considering a technology that has positive
incremental costs and incremental QALYs, the proximity
of the mean ICER to the ‘cost-effectiveness threshold’
being used in the analysis.8 When the ICER is close to the
‘cost-effectiveness threshold’, ceteris paribus, then it is
more likely that the decision is going to be uncertain. The
other factor is the uncertainty of the estimated ICER (in
this case driven by the variability in incremental costs).
The variability of costs (and incremental costs) is likely to
increase with the addition of cost categories, unless a
negative correlation exists between the costs within the
narrower category and those only within the broader
category.
Where there is no extension of life effect from a treat-
ment, including unrelated costs will not affect the mean
ICER, in expectation, as these additional costs would be
the same on average regardless of treatment received.
Decision uncertainty, however, will be affected given the
variability of costs. As such, under these circumstances, the
addition of truly unrelated costs amounts to adding noise
and increased variability into the model.
Adding noise and variability can lead to greater uncer-
tainty and there are two reasons why this might be a con-
cern. The first is that there will be reduced power to detect
a statistically significant effect, since standard errors will
increase. The second concern, more prevalent within health
economic evaluation, is that the decision uncertainty will
be inflated, thus reducing the probability of making the
right decision. Of course, the analyst will never know what
is truly related and truly unrelated and so identifying
something as noise with certainty is impossible. This is not
Fig. 4 Frequency plot of net health benefits under three scenarios. CHD coronary heart disease, CVD cardiovascular disease, QALYs quality-
adjusted life-years
8 In other words, the proximity of the mean net health benefit of the
technology to zero.
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to say that unrelated costs should never be included
because of the potential of introducing noise, but it is
important to consider the implications of adding in what
might be truly unrelated costs in normal years of life. This
issue has been overlooked in the literature on this topic to
date.
As already discussed, there is reason to caution against
including unrelated costs in some cases where there is no
(or little) mortality effect. In addition, obtaining data on
unrelated costs may not be without cost to the analyst,
especially obtaining data that are both very unlikely to be
related and are realised many years in the future—although
this may be getting less costly with time [4] as a growing
number of sources exist that can be used to provide data for
unrelated costs in extended years of life across a number of
different countries [30–34].
Lack of appropriate and robust data will be an issue in
many circumstances. Experimental evidence typically
does not have a sufficiently long time horizon to identify
the occurrence of all future related and unrelated events
and their associated costs. As an alternative, the use of
observational data from administrative sources is becom-
ing increasingly prevalent and is well-suited to estimate
parameters with large numbers of observations. Observa-
tional data are typically collected over a longer period of
time; however, by design it is not as robust as randomised
trial data when it comes to estimating the incremental cost
caused by treatment, with potential bias coming from
unobserved confounding and selection effects. With both
randomised controlled trial (RCT) and observational evi-
dence there is the issue of sufficient breadth of study
design to identify all related and unrelated costs. By their
very nature, such studies would be unlikely to be focused
on collecting events unrelated to the primary intervention
and, as such, data collection would have to be sufficiently
flexible or broad to capture all costs (related and unre-
lated). Routine data sources, such as HES in the UK
context, which capture all healthcare-related interventions
and hospital visits are another possibility. HES has
recently been used to compute average costs by age, sex
and index of multiple deprivation (IMD) group [34]. This
source has the potential to be very useful for incorporation
into decision models, but there are two limitations that
provide scope for future research. The first is that the costs
in this paper include both related and unrelated costs,
meaning that researchers would need to adapt its results in
order to include it alongside related costs in extended
years of life estimated as part of the model [33]. The
second limitation is that the costs of the patient population
at hand may not be well represented by the national
average on account of the relationship between costs and
co-morbidities. In such circumstances, disentangling the
associations between costs, age and morbidities will be
required for the precise estimation of parameters capturing
unrelated costs. There is already a growing understanding
of the causal effect that age has on costs, which has been
found to be questionable. In the first instance, age was
considered to be a ‘red herring’, with costs increasing with
age due only to a spurious association, and the underlying
effect on costs deriving from time until death and not age
itself [35, 36]. More recently, research has started to
question whether this red herring hypothesis is itself a red
herring, with researchers analysing the effects of mor-
bidity and multi-morbidity on costs in greater depth
[37, 38]. Despite these limitations and challenges it is
likely that, with further research, electronic health records
will be increasingly utilised for the incorporation of
unrelated costs in extended years of life where this is
deemed appropriate.
Even in the absence of observational data, it is still
possible to place a reasonable estimate on these future
unrelated costs parameters. There are methods that can be
used to illustrate the potential range values for these
parameters, reflecting their degree of uncertainty [39]. This
can then be used to guide future research priorities [40]. To
inform these uncertain estimates, expert elicitation meth-
ods could be useful. In some circumstances, even where
long-term observational data are not available, clinical
experts may have experience of observing events occurring
in survivors of acute MI over a long enough period. This
clinical experience can be used to generate distributions for
these unrelated future costs, reflecting a large amount of
uncertainty around the estimates. All things considered,
lack of data is certainly a challenge, but this seems more of
a practical obstacle to overcome (if these data are poten-
tially influential to the decision) rather than a reason for
exclusion.
4.1 Limitations
Because the model itself concerns a hypothetical inter-
vention, the specific results should not be over-interpreted,
nor can they be generalised for assessments of how much
of an impact the inclusion of unrelated costs will have in
different contexts. The results do allow us to identify the
types of effects that will result from including unrelated
costs. To put this another way, this paper contributes to the
literature by illustrating which costs matter and why, but
should not be used to say how much different costs matter
outside of the context analysed. For example, within the
context analysed, it can be seen that the variability of
incremental costs is generally low, irrespective of which
costing scenario is used. This results from the large number
of observations upon which the system of equations is
estimated, and hence granting a degree of precision that
would not be attainable in smaller studies.
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5 Conclusions
It is suggested that economic evaluations should include
estimates of incremental healthcare costs that fall within
the healthcare budget and not just the intervention costs
associated with the treatment. However, in moving beyond
intervention costs, the analyst faces challenges in deter-
mining which healthcare costs (unrelated and unrelated)
are truly caused by the treatment, which can be particularly
demanding when there are variable and noisy cost data, and
when the knowledge around the natural history of a disease
is not well-known, as in the case of acute MI survivorship.
With an aging and co-morbid population, the inclusion of
all healthcare costs may have important ramifications for
the selection of healthcare provision on economic grounds.
This paper contributes to this discussion by illustrating
the importance of different types of costs—which costs
matter—in the context of SCAD, where little is known
about what is truly related or unrelated and there is con-
siderable variation in analytical practice concerning cost
categories to include in economic evaluation. It has been
shown that costs matter, not just in terms of the point
estimate of cost effectiveness, the expected ICER, but also
in terms of decision uncertainty. Where adding unrelated
costs in evaluations without an impact on survival, this
may simply add noise to the data and therefore will reduce
the probability of making the right decision.
The inclusion of unrelated costs is important, especially
when the treatment is expected to extend life, and so
including all cost categories is at least recommended as a
sensitivity analysis (if the associated cost to analyst of
obtaining data is not prohibitively high).
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